- Home
- ZVIA vs ACRS Comparison
ZVIA vs ACRS Comparison
Compare ZVIA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- ACRS
- Stock Information
- Founded
- ZVIA 2007
- ACRS 2012
- Country
- ZVIA United States
- ACRS United States
- Employees
- ZVIA N/A
- ACRS N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- ACRS Health Care
- Exchange
- ZVIA Nasdaq
- ACRS Nasdaq
- Market Cap
- ZVIA 193.4M
- ACRS 198.2M
- IPO Year
- ZVIA 2021
- ACRS 2015
- Fundamental
- Price
- ZVIA $2.66
- ACRS $2.29
- Analyst Decision
- ZVIA Buy
- ACRS Strong Buy
- Analyst Count
- ZVIA 5
- ACRS 9
- Target Price
- ZVIA $4.89
- ACRS $9.25
- AVG Volume (30 Days)
- ZVIA 779.4K
- ACRS 1.5M
- Earning Date
- ZVIA 11-05-2025
- ACRS 11-06-2025
- Dividend Yield
- ZVIA N/A
- ACRS N/A
- EPS Growth
- ZVIA N/A
- ACRS N/A
- EPS
- ZVIA N/A
- ACRS N/A
- Revenue
- ZVIA $162,849,000.00
- ACRS $15,742,000.00
- Revenue This Year
- ZVIA $6.44
- ACRS N/A
- Revenue Next Year
- ZVIA $6.68
- ACRS N/A
- P/E Ratio
- ZVIA N/A
- ACRS N/A
- Revenue Growth
- ZVIA 6.17
- ACRS N/A
- 52 Week Low
- ZVIA $0.96
- ACRS $1.05
- 52 Week High
- ZVIA $4.99
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- ZVIA 54.07
- ACRS 54.50
- Support Level
- ZVIA $2.29
- ACRS $2.13
- Resistance Level
- ZVIA $2.42
- ACRS $2.70
- Average True Range (ATR)
- ZVIA 0.12
- ACRS 0.25
- MACD
- ZVIA 0.02
- ACRS -0.00
- Stochastic Oscillator
- ZVIA 52.50
- ACRS 46.75
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.